ESC 365 - Investigation of the prevalence of cardiac amyloidosis among patients with echocardiographically verified myocardial hypertrophy of unknown etiology

Open Access

Investigation of the prevalence of cardiac amyloidosis among patients with echocardiographically verified myocardial hypertrophy of unknown etiology

Session: ePosters in myocardial disease - hypertrophic cardiomyopathy (1)

Topic: Hypertrophic Cardiomyopathy

Speaker: Doctor N. Gataric (Belgrade, RS)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Doctor Nina Gataric

University Clinical Center of Serbia, Belgrade (Serbia)

2 presentations

0 follower

6 more presentations in this session

Review of variants of uncertain significance in hypertrophic cardiomyopathy: a single-center multi-ethnic population experience

Speaker: Doctor B. Chung (Kuching, MY)

Understanding the patient burden in transthyretin cardiac amyloidosis is significantly improved with continuing medical education

Speaker: Doctor C. Rohani-Montez (London, GB)

Diagnostic performance of right ventricle wall thickness, strain, and their ratio in differentiating Fabry cardiomyopathy from wild-type transthyretin cardiac amyloidosis

Speaker: Doctor E. Mata (Creixomil, PT)

Change of 3D echocardiographic parameters in obstructive hypertrophic cardiomyopathy during mavacamten treatment

Speaker: Doctor R. Sepp (Szeged, HU)

Assessment of changes in right-sided cardiac echocardiographic parameters in obstructive hypertrophic cardiomyopathy during mavacamten treatment

Speaker: Doctor R. Sepp (Szeged, HU)

Access the full session

ePosters in myocardial disease - hypertrophic cardiomyopathy (1)

Speakers: Doctor N. Gataric, Doctor B. Chung, Doctor C. Rohani-Montez, Doctor E. Mata, Doctor R. Sepp...

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources